Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Analysis of DNA Interstrand Cross-Links and their Repair by Modified Comet Assay.

Swift LP, Castle L, McHugh PJ.

Methods Mol Biol. 2020;2119:79-88. doi: 10.1007/978-1-0716-0323-9_7.

PMID:
31989516
2.

XPF protein levels determine sensitivity of malignant melanoma cells to oxaliplatin chemotherapy: suitability as a biomarker for patient selection.

Hatch SB, Swift LP, Caporali S, Carter R, Hill EJ, MacGregor TP, D'Atri S, Middleton MR, McHugh PJ, Sharma RA.

Int J Cancer. 2014 Mar 15;134(6):1495-503. doi: 10.1002/ijc.28454. Epub 2013 Nov 14.

3.

The hydroxyl epimer of doxorubicin controls the rate of formation of cytotoxic anthracycline-DNA adducts.

Forrest RA, Swift LP, Evison BJ, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Chemother Pharmacol. 2013 Mar;71(3):809-16. doi: 10.1007/s00280-012-2049-x. Epub 2012 Dec 23.

PMID:
23263186
4.

Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation.

Forrest RA, Swift LP, Rephaeli A, Nudelman A, Kimura K, Phillips DR, Cutts SM.

Biochem Pharmacol. 2012 Jun 15;83(12):1602-12. doi: 10.1016/j.bcp.2012.02.026. Epub 2012 Mar 5.

PMID:
22414726
5.

Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair.

Wang AT, Sengerov√° B, Cattell E, Inagawa T, Hartley JM, Kiakos K, Burgess-Brown NA, Swift LP, Enzlin JH, Schofield CJ, Gileadi O, Hartley JA, McHugh PJ.

Genes Dev. 2011 Sep 1;25(17):1859-70. doi: 10.1101/gad.15699211.

6.

Barminomycin, a model for the development of new anthracyclines.

Kimura K, Spencer DM, Bilardi R, Swift LP, Box AJ, Brownlee RT, Cutts SM, Phillips DR.

Anticancer Agents Med Chem. 2010 Jan;10(1):70-7. Review.

PMID:
19807684
7.

Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species.

Levovich I, Nudelman A, Berkovitch G, Swift LP, Cutts SM, Phillips DR, Rephaeli A.

Cancer Chemother Pharmacol. 2008 Aug;62(3):471-82. Epub 2007 Nov 21.

PMID:
18030472
8.

The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.

Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR.

Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. Epub 2007 Jun 27.

PMID:
17594094
9.

Activation of clinically used anthracyclines by the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate.

Cutts SM, Swift LP, Pillay V, Forrest RA, Nudelman A, Rephaeli A, Phillips DR.

Mol Cancer Ther. 2007 Apr;6(4):1450-9.

10.

Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death.

Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM.

Cancer Res. 2006 May 1;66(9):4863-71.

11.

Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Curr Med Chem Anticancer Agents. 2005 Sep;5(5):431-47. Review.

PMID:
16178771
12.

Sequence specificity of adriamycin-DNA adducts in human tumor cells.

Cutts SM, Swift LP, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Jul;2(7):661-70.

13.

Activation of adriamycin by the pH-dependent formaldehyde-releasing prodrug hexamethylenetetramine.

Swift LP, Cutts SM, Rephaeli A, Nudelman A, Phillips DR.

Mol Cancer Ther. 2003 Feb;2(2):189-98.

14.

Structural requirements for the formation of anthracycline-DNA adducts.

Cutts SM, Parker BS, Swift LP, Kimura KI, Phillips DR.

Anticancer Drug Des. 2000 Oct;15(5):373-86.

PMID:
11354313

Supplemental Content

Loading ...
Support Center